Form 8-K Cullinan Therapeutics, For: Aug 08
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Cullinan Oncology Inc. (CGEM) PT Lowered to $38 at Morgan Stanley
August 8, 2024 11:56 AM EDTMorgan Stanley analyst Jeffrey Hung lowered the price target on Cullinan Oncology Inc. (NASDAQ: CGEM) to $38.00 (from $40.00) while maintaining a Overweight rating.
The analyst comments "With earnings, Cullinan reported multiple updates across its portfolio. The biggest update is that the company will pursue rheumatoid arthritis (RA) as... More
